Yonsei Med J.  2013 Nov;54(6):1438-1446. 10.3349/ymj.2013.54.6.1438.

Iodinated Contrast Media Can Induce Long-Lasting Oxidative Stress in Hemodialysis Patients

• Hwang SD
• Kim YJ
• Lee SH
• Cho DK
• Cho YH
• Moon SJ
• Lee SC
• Yoon SY

• KMID: 1798141
• DOI: http://doi.org/10.3349/ymj.2013.54.6.1438

Abstract

PURPOSE
Due to their comorbidities, dialysis patients have many chances to undergo radiologic procedures using iodinated contrast media. We aimed to assess time-sequenced blood oxidative stress level after contrast exposure in hemodialysis (HD) patients compared to those in the non-dialysis population.
MATERIALS AND METHODS
We included 21 anuric HD patients [HD-coronary angiography (CAG) group] and 23 persons with normal renal function (nonHD-CAG group) scheduled for CAG, and assessed 4 oxidative stress markers [advanced oxidation protein products (AOPP); catalase; 8-hydroxydeoxyguanosine; and malondialdehyde] before and after CAG, and subsequently up to 28 days.
RESULTS
In the nonHD-CAG group, only AOPP increased immediately after CAG and returned to baseline within one day. However, in the HD-CAG group, all four oxidative stress markers were significantly increased starting one day after CAG, and remained elevated longer than those in the nonHD-CAG group. Especially, AOPP level remained elevated for a month after contrast exposure.
CONCLUSION
Our study showed that iodinated contrast media induces severe and prolonged oxidative stress in HD patients.

Keyword

Oxidative stress; contrast media; hemodialysis

MeSH Terms

Aged
Contrast Media/*adverse effects
Female
Humans
Male
Middle Aged
Oxidative Stress/*drug effects
Renal Dialysis/*adverse effects
Contrast Media

Figure

• 

  Fig. 1 Changes in the oxidative stress markers after CAG. *p<0.05 vs. baseline. †p<0.05 vs. nonHD-CAG group. ‡p<0.05 vs. HD-control. AOPP, advanced oxidation protein products; 8-OHdG, 8-hydroxydeoxyguanosine; MDA, malondialdehyde; HD, hemodialysis; CAG, coronary angiography.

Reference

1. McCullough PA. Contrast-induced acute kidney injury. J Am Coll Cardiol. 2008; 51:1419–1428.

2. Lai HM, Aronow WS, Chugh SS, Pudasaini B, Goel A, Garrick R. Risk factors for hemodialysis and mortality in patients with contrast-induced nephropathy. Am J Ther. 2012; [Epub ahead of print].

3. Bolognese L, Falsini G, Schwenke C, Grotti S, Limbruno U, Liistro F, et al. Impact of iso-osmolar versus low-osmolar contrast agents on contrast-induced nephropathy and tissue reperfusion in unselected patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention (from the Contrast Media and Nephrotoxicity Following Primary Angioplasty for Acute Myocardial Infarction [CONTRAST-AMI] Trial). Am J Cardiol. 2012; 109:67–74.

4. Chen SL, Zhang J, Yei F, Zhu Z, Liu Z, Lin S, et al. Clinical outcomes of contrast-induced nephropathy in patients undergoing percutaneous coronary intervention: a prospective, multicenter, randomized study to analyze the effect of hydration and acetylcysteine. Int J Cardiol. 2008; 126:407–413.

5. Lee SW, Kim WJ, Kim YH, Park SW, Park DW, Yun SC, et al. Preventive strategies of renal insufficiency in patients with diabetes undergoing intervention or arteriography (the PREVENT Trial). Am J Cardiol. 2011; 107:1447–1452.

6. Nora NA, Krumlovsky FA. Use of iodinated contrast media in patients with chronic renal insufficiency and in end-stage renal disease. Int J Artif Organs. 1991; 14:196–198.

7. Janousek R, Krajina A, Peregrin JH, Dusilova-Sulkova S, Renc O, Hajek J, et al. Effect of intravascular iodinated contrast media on natural course of end-stage renal disease progression in hemodialysis patients: a prospective study. Cardiovasc Intervent Radiol. 2010; 33:61–66.

8. Witko-Sarsat V, Friedlander M, Capeillère-Blandin C, Nguyen-Khoa T, Nguyen AT, Zingraff J, et al. Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int. 1996; 49:1304–1313.

9. Bevan RJ, Durand MF, Hickenbotham PT, Kitas GD, Patel PR, Podmore ID, et al. Validation of a novel ELISA for measurement of MDA-LDL in human plasma. Free Radic Biol Med. 2003; 35:517–527.

10. Shimoi K, Kasai H, Yokota N, Toyokuni S, Kinae N. Comparison between high-performance liquid chromatography and enzyme-linked immunosorbent assay for the determination of 8-hydroxy-2'-deoxyguanosine in human urine. Cancer Epidemiol Biomarkers Prev. 2002; 11:767–770.

11. Nawaz SK, Hasnain S. Effects of noise exposure on catalase activity of growing lymphocytes. Bosn J Basic Med Sci. 2011; 11:219–222.

12. Stewart JH, Buccianti G, Agodoa L, Gellert R, McCredie MR, Lowenfels AB, et al. Cancers of the kidney and urinary tract in patients on dialysis for end-stage renal disease: analysis of data from the United States, Europe, and Australia and New Zealand. J Am Soc Nephrol. 2003; 14:197–207.

13. Tseng GY, Lin HJ, Fang CT, Yang HB, Tseng GC, Wang PC, et al. Recurrence of peptic ulcer in uraemic and non-uraemic patients after Helicobacter pylori eradication: a 2-year study. Aliment Pharmacol Ther. 2007; 26:925–933.

14. Cheung J, Yu A, LaBossiere J, Zhu Q, Fedorak RN. Peptic ulcer bleeding outcomes adversely affected by end-stage renal disease. Gastrointest Endosc. 2010; 71:44–49.

15. Hallan S, Astor B, Romundstad S, Aasarød K, Kvenild K, Coresh J. Association of kidney function and albuminuria with cardiovascular mortality in older vs younger individuals: The HUNT II Study. Arch Intern Med. 2007; 167:2490–2496.

16. Persson PB, Hansell P, Liss P. Pathophysiology of contrast medium-induced nephropathy. Kidney Int. 2005; 68:14–22.

17. Rudnick MR, Goldfarb S, Wexler L, Ludbrook PA, Murphy MJ, Halpern EF, et al. Nephrotoxicity of ionic and nonionic contrast media in 1196 patients: a randomized trial. The Iohexol Cooperative Study. Kidney Int. 1995; 47:254–261.

18. Seeliger E, Becker K, Ladwig M, Wronski T, Persson PB, Flemming B. Up to 50-fold increase in urine viscosity with iso-osmolar contrast media in the rat. Radiology. 2010; 256:406–414.

19. Sendeski M, Patzak A, Pallone TL, Cao C, Persson AE, Persson PB. Iodixanol, constriction of medullary descending vasa recta, and risk for contrast medium-induced nephropathy. Radiology. 2009; 251:697–704.

20. Dascalu A, Peer A. Effects of radiologic contrast media on human endothelial and kidney cell lines: intracellular pH and cytotoxicity. Acad Radiol. 1994; 1:145–150.

21. Furuta W, Yamauchi A, Dohgu S, Nakagawa S, Sendo T, Makino K, et al. Contrast media increase vascular endothelial permeability by inhibiting nitric-oxide production. Invest Radiol. 2002; 37:13–19.

22. Heyman SN, Rosen S, Khamaisi M, Idée JM, Rosenberger C. Reactive oxygen species and the pathogenesis of radiocontrast-induced nephropathy. Invest Radiol. 2010; 45:188–195.

23. Thiele H, Hildebrand L, Schirdewahn C, Eitel I, Adams V, Fuernau G, et al. Impact of high-dose N-acetylcysteine versus placebo on contrast-induced nephropathy and myocardial reperfusion injury in unselected patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. The LIPSIA-N-ACC (Prospective, Single-Blind, Placebo-Controlled, Randomized Leipzig Immediate PercutaneouS Coronary Intervention Acute Myocardial Infarction N-ACC) Trial. J Am Coll Cardiol. 2010; 55:2201–2209.

24. Haeussler U, Riedel M, Keller F. Free reactive oxygen species and nephrotoxicity of contrast agents. Kidney Blood Press Res. 2004; 27:167–171.

25. Jo SH, Koo BK, Park JS, Kang HJ, Kim YJ, Kim HL, et al. N-acetylcysteine versus AScorbic acid for preventing contrast-Induced nephropathy in patients with renal insufficiency undergoing coronary angiography NASPI study-a prospective randomized controlled trial. Am Heart J. 2009; 157:576–583.

26. Tasanarong A, Piyayotai D, Thitiarchakul S. Protection of radiocontrast induced nephropathy by vitamin E (alpha tocopherol): a randomized controlled pilot study. J Med Assoc Thai. 2009; 92:1273–1281.

27. Kandula P, Shah R, Singh N, Markwell SJ, Bhensdadia N, Navaneethan SD. Statins for prevention of contrast-induced nephropathy in patients undergoing non-emergent percutaneous coronary intervention. Nephrology (Carlton). 2010; 15:165–170.

28. Svaland MG, Haider T, Langseth-Manrique K, Andrew E, Hals PA. Human pharmacokinetics of iodixanol. Invest Radiol. 1992; 27:130–133.

29. Berg KJ, Rolfsen B, Stake G. Iodixanol is readily eliminated by hemodialysis. Acta Radiol. 1998; 39:372–374.

30. Bailie GR, Eisele G, Sala J, Wu D. Determination of iodixanol hemodialysis clearance using a novel in vitro system. Clin Res Regul Aff. 1996; 13:111–124.

31. Essick EE, Sam F. Oxidative stress and autophagy in cardiac disease, neurological disorders, aging and cancer. Oxid Med Cell Longev. 2010; 3:168–177.

32. Ozgocmen S, Ozyurt H, Sogut S, Akyol O. Current concepts in the pathophysiology of fibromyalgia: the potential role of oxidative stress and nitric oxide. Rheumatol Int. 2006; 26:585–597.

33. Logan AC, Wong C. Chronic fatigue syndrome: oxidative stress and dietary modifications. Altern Med Rev. 2001; 6:450–459.

34. Taki K, Takayama F, Tsuruta Y, Niwa T. Oxidative stress, advanced glycation end product, and coronary artery calcification in hemodialysis patients. Kidney Int. 2006; 70:218–224.

35. Miyazaki H, Matsuoka H, Itabe H, Usui M, Ueda S, Okuda S, et al. Hemodialysis impairs endothelial function via oxidative stress: effects of vitamin E-coated dialyzer. Circulation. 2000; 101:1002–1006.

36. Barsotti A, Fabbi P, Fedele M, Garibaldi S, Balbi M, Bezante GP, et al. Role of advanced oxidation protein products and Thiol ratio in patients with acute coronary syndromes. Clin Biochem. 2011; 44:605–611.

37. Skvarilová M, Bulava A, Stejskal D, Adamovská S, Bartek J. Increased level of advanced oxidation products (AOPP) as a marker of oxidative stress in patients with acute coronary syndrome. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2005; 149:83–87.

38. Xiang F, Shuanglun X, Jingfeng W, Ruqiong N, Yuan Z, Yongqing L, et al. Association of serum 8-hydroxy-2'-deoxyguanosine levels with the presence and severity of coronary artery disease. Coron Artery Dis. 2011; 22:223–227.

39. Surekha RH, Srikanth BB, Jharna P, Ramachandra RV, Dayasagar RV, Jyothy A. Oxidative stress and total antioxidant status in myocardial infarction. Singapore Med J. 2007; 48:137–142.

40. Mutlu-Türkoğlu U, Akalin Z, Ilhan E, Yilmaz E, Bilge A, Nişanci Y, et al. Increased plasma malondialdehyde and protein carbonyl levels and lymphocyte DNA damage in patients with angiographically defined coronary artery disease. Clin Biochem. 2005; 38:1059–1065.

41. Gutteridge JM. Lipid peroxidation and antioxidants as biomarkers of tissue damage. Clin Chem. 1995; 41(12 Pt 2):1819–1828.

42. Guo CH, Wang CL, Chen PC, Yang TC. Linkage of some trace elements, peripheral blood lymphocytes, inflammation, and oxidative stress in patients undergoing either hemodialysis or peritoneal dialysis. Perit Dial Int. 2011; 31:583–591.

43. Knap B, Prezelj M, Buturović-Ponikvar J, Ponikvar R, Bren AF. Antioxidant enzymes show adaptation to oxidative stress in athletes and increased stress in hemodialysis patients. Ther Apher Dial. 2009; 13:300–305.

44. Chen CK, Liaw JM, Juang JG, Lin TH. Antioxidant enzymes and trace elements in hemodialyzed patients. Biol Trace Elem Res. 1997; 58:149–157.

45. Kesavulu MM, Rao BK, Giri R, Vijaya J, Subramanyam G, Apparao C. Lipid peroxidation and antioxidant enzyme status in Type 2 diabetics with coronary heart disease. Diabetes Res Clin Pract. 2001; 53:33–39.

46. Saha A, Adak S, Chowdhury S, Bhattacharyya M. Enhanced oxygen releasing capacity and oxidative stress in diabetes mellitus and diabetes mellitus-associated cardiovascular disease: a comparative study. Clin Chim Acta. 2005; 361:141–149.

47. Dwivedi VK, Chandra M, Misra PC, Misra A, Misra MK. Status of some free radical scavenging enzymes in the blood of myocardial infarction patients. J Enzyme Inhib Med Chem. 2006; 21:43–46.

48. Rajbala , Sane AS, Upadhyay AR, Mishra VV, Trivedi HL. Iodinated contrast media induced oxidative stress status in patients undergoing urography. Panminerva Med. 2000; 42:119–122.

49. Fatouros IG, Pasadakis P, Sovatzidis A, Chatzinikolaou A, Panagoutsos S, Sivridis D, et al. Acute exercise may exacerbate oxidative stress response in hemodialysis patients. Nephron Clin Pract. 2008; 109:c55–c64.

50. Keeley EC, Kadakia R, Soman S, Borzak S, McCullough PA. Analysis of long-term survival after revascularization in patients with chronic kidney disease presenting with acute coronary syndromes. Am J Cardiol. 2003; 92:509–514.

51. Ix JH, Mercado N, Shlipak MG, Lemos PA, Boersma E, Lindeboom W, et al. Association of chronic kidney disease with clinical outcomes after coronary revascularization: the Arterial Revascularization Therapies Study (ARTS). Am Heart J. 2005; 149:512–519.

52. Feng Y, Shen C, Ma G, Wang J, Chen Z, Dai Q, et al. Prolonged pain to hospital time is associated with increased plasma advanced oxidation protein products and poor prognosis in patients with percutaneous coronary intervention for ST-elevation myocardial infarction. Heart Vessels. 2010; 25:374–378.

53. Whaley-Connell A, McCullough PA, Sowers JR. The role of oxidative stress in the metabolic syndrome. Rev Cardiovasc Med. 2011; 12:21–29.

54. Shah SV, Baliga R, Rajapurkar M, Fonseca VA. Oxidants in chronic kidney disease. J Am Soc Nephrol. 2007; 18:16–28.

55. Lele S, Shah S, McCullough PA, Rajapurkar M. Serum catalytic iron as a novel biomarker of vascular injury in acute coronary syndromes. EuroIntervention. 2009; 5:336–342.

56. Kinsella SM, Coyle JP, Long EB, McWilliams SR, Maher MM, Clarkson MR, et al. Maintenance hemodialysis patients have high cumulative radiation exposure. Kidney Int. 2010; 78:789–793.

57. De Mauri A, Brambilla M, Chiarinotti D, Matheoud R, Carriero A, De Leo M. Estimated radiation exposure from medical imaging in hemodialysis patients. J Am Soc Nephrol. 2011; 22:571–578.

58. Marenzi G, Assanelli E, Marana I, Lauri G, Campodonico J, Grazi M, et al. N-acetylcysteine and contrast-induced nephropathy in primary angioplasty. N Engl J Med. 2006; 354:2773–2782.